Moleculin Biotech

132 articles with Moleculin Biotech

• Moleculin to Present at the H.C. Wainwright BioConnect 2021 Conference

  1/7/2021

   Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that members of management will present at the virtual H.C. Wainwright BioConnect 2021 Conference being held January 11-14, 202

• Moleculin Announces Annamycin Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas

  12/29/2020

  Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Annamycin for treatment of soft ti

• Moleculin Announces FDA Permission to Begin Clinical Study of Annamycin for Sarcoma Lung Metastases

  12/17/2020

  Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the US Food and Drug Administration (FDA) is allowing the company's Investigational New Drug (IND) application to study Annamycin for the treatment of soft tissue sarcoma lung metastases to go into effect

• Moleculin To Present Antitumor Activity of Annamycin in Combination with Ara-C in AML at American Society for Hematology Annual Conference

  12/3/2020

   Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it will present animal data demonstrating highly improved activity against acute myeloid leukemia ("AML") in combination w

• 

  FDA Works to Get New Drugs to Patients Faster with Multiple Approvals This Week

  12/2/2020

  The FDA uses special designations to get new, breakthrough treatments to patients in the greatest need.

• Moleculin Announces New Data Demonstrating Synergistic Antitumor Activity of Annamycin Combination with Ara-C in AML

  11/19/2020

   Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that new an

• Moleculin Biotech, Inc. Reports Financial Results for the Quarter Ended September 30, 2020

  11/13/2020

   Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced its financial results for the quarter ended September 30, 2020 and provided a business update.

• Moleculin Announces Additional Collaboration on Drug Candidate Targeting COVID-19

  10/29/2020

  Initial information sharing agreement signed to further research into the anti-viral potential of WP1122

• Moleculin to Participate in Panel at ROTH Capital's "COVID-19 Therapeutics in Development" Healthcare Event

  10/27/2020

  Moleculin Biotech, Inc. announced that members of management will participate in a panel at ROTH Capital's healthcare event titled, "COVID-19 Therapeutics in Development," taking place on Wednesday, October 28th, 2020.

• Moleculin Announces Independent Study Validates Annamycin's Ability to Target Lung Localized Tumors

  10/21/2020

  Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, announced results from an independent laboratory validating internal animal studies showing the ability of Annamycin to target lung localized tumors.

• Moleculin Announces Additional Positive Interim Results in Adult Glioblastoma Clinical Trial

  10/13/2020

  Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses

• Moleculin Announces New Antiviral Drug Candidates Demonstrate In Vitro Activity Against HIV

  10/6/2020

  Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, announced preliminary new findings from its

• Moleculin Appoints Elizabeth Cermak to Board of Directors

  10/5/2020

  Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates  targeting significant unmet needs in the treatment of tumors and viruses, today announced the appointment of Elizabeth (Liz) Cermak , an accomplished life sciences board direc

• Moleculin Announces Positive Interim Results in Pediatric Brain Tumor Phase 1 Clinical Trial at Emory University

  10/1/2020

   Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, a

• Moleculin Announces Discovery of Significant In Vitro Activity Against COVID-19 Virus for New Antimetabolites

  9/29/2020

  Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, announced that its research team has discovered that a molecule within its portfolio of antimetabolites has displayed significant in vitro antiviral activity against SARS-CoV-2.

• Moleculin Announces COVID-19 In Vivo Testing Contracted for WP1122

  9/14/2020

  Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it has contracted with an independent labora

• Moleculin to Present at Upcoming Healthcare Investor Conferences

  9/10/2020

  Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that members of management will present virtually at the H.C. Wainwright & Co. 22 nd Annual Global Investment Confe

• Moleculin Announces Successful Completion of Pre-IND Meeting with the FDA

  9/9/2020

   Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses

• Moleculin to Present at LD Micro 500 Virtual Investor Conference

  8/27/2020

  Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that Walter Klemp , Chairman and Chief Executive Officer, will present at the LD Micro 500 Virtual Investor Conference being held virtu

• Moleculin Biotech, Inc. Reports Financial Results for the Quarter Ended June 30, 2020

  8/12/2020

  Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, announced its financial results for the quarter ended June 30, 2020 and provided a business update.